131179-95-8
中文名称
乙丙昔罗
英文名称
Efaproxiral
CAS
131179-95-8
分子式
C20H23NO4
分子量
341.4
MOL 文件
131179-95-8.mol
更新日期
2023/03/20 15:41:21
131179-95-8 结构式
基本信息
中文别名
乙丙昔罗2-[4-(3,5-二甲基苯基氨基甲酰甲基)苯氧基]-2-甲基丙酸
2-(4-(((3,5-二甲基苯胺)羰基)甲基)苯氧基)-2-甲基丙酸
2-[4-(3,5-二甲基苯基氨基甲酰甲基)苯氧基]-2-甲基丙酸,乙丙昔罗自由酸
英文别名
faproxiralEfaproxiral
EFAPROXIRALUM
Efaproxiral free acid
EFAPROXIRAL
EFAPROXIRAL FREE ACID
FAPROXIRAL
2-[4-(3,5-Dimethylphenylcarbamoylmethyl)phenoxy]-2-methylpropionic acid
2-(4-(((3,5-dimethylanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid
Propanoic acid, 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-
所属类别
生物化工：激动剂抑制剂物理化学性质
熔点48-50°C
沸点554.5±50.0 °C(Predicted)
密度1.202±0.06 g/cm3(Predicted)
储存条件Refrigerator
溶解度可溶于DMSO（少许）、甲醇（少许）
酸度系数(pKa)3.26±0.10(Predicted)
形态固体
颜色灰白色到棕褐色
乙丙昔罗价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-13619 | 乙丙昔罗 Efaproxiral | 131179-95-8 | 50mg | 700元 |
| 2024/04/30 | HY-13619 | 乙丙昔罗 Efaproxiral | 131179-95-8 | 10mM * 1mLin DMSO | 770元 |
| 2024/04/30 | HY-13619 | 乙丙昔罗 Efaproxiral | 131179-95-8 | 1g | 6000元 |
常见问题列表
生物活性
Efaproxiral (RSR13) 是一种血红蛋白 (Hb) 合成变构调节剂, 能降低血红蛋白氧 (O2) 的结合亲和力，增强放射处理中缺氧肿瘤的氧合作用。靶点
haemoglobin (Hb)
体外研究
Efaproxiral binds to only one pair of symmetry-related sites in the Hb central water cavity.
Efaproxiral readily crosses the red cell membrane in the presence of serum albumin solutions.
Efaproxiral is not inhibited from entering erythrocytes in the presence of an anion-channel blocking agent (DIDS).
体内研究
Efaproxiral (150 mg/kg, i.p.) increase tumor oxygenation，and increase the tumor growth inhibition of radiotherapy over 5 days of treatment.
Efaproxiral reduces hemoglobin-oxygen binding affinity, which facilitates oxygen release from hemoglobin into surrounding tissues and potentially increases the pO(2) of the tumors
| Animal Model: | Female C3H/HEJ mice (18–20 g), with radiation-induced fibrosarcoma tumor (RIF-1) cells xenograft |
| Dosage: | 150 mg/kg |
| Administration: | Intraperitoneal injection; prior to X Irradiation (4 Gy/day), for 5 days |
| Result: | Significantly increased tumor oxygenation by 8.4 to 43.4 mmHg within 5 days, with maximum increases at 22–31 minutes after treatment. |